Sklerostin ve TWEAK’in Periodontitis Teşhisindeki Rolü

Yıl 2023, Cilt: 10 Sayı: 1, 130 - 133, 27.04.2023

Ece Güner , Gülay Tüter

https://doi.org/10.15311/selcukdentj.1099163

Öz

Periodontitis multifaktöriyel etiyolojisi olan kronik inflamatuar bir hastalıktır. Hastalık biofilm içerisindeki patojenler tarafından başlatılmaktadır. Hastalık ilerledikten sonra görülen doku yıkımı konağa ait koruyucu ve yıkıcı mekanizmalar arasındaki dengesizlikten kaynaklanır. Periodontal hastalığın teşhisinde kullanılan geleneksel yöntemler, hastalık aktivitesi ve prognozuna ilişkin bilgi vermemektedir. Bu konuda son yıllarda sklerostin ve tümör nekroz faktörü benzeri zayıf apoptoz indükleyicisinin (TWEAK) inflamasyon ve kemik metabolizması üzerindeki etkileri incelenmeye başlanmıştır. Bu derlemenin amacı, sklerostin ve TWEAK’in periodontal hastalık patogenezindeki rolünün değerlendirilmesi ve sklerostin ve TWEAK’in periodontal hastalık teşhisi için yararlı birer biyobelirteç olup olmadığının incelenmesidir.

Anahtar Kelimeler

Sklerostin, TWEAK, Periodontitis, Dişeti oluğu sıvısı, Tükürük

Kaynakça

• Miller CS, King Jr CP, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: a cross-sectional study. The Journal of the American Dental Association 2006;137:322-329.
• Pan W, Wang Q, Chen Q. The cytokine network involved in the host immune response to periodontitis. International journal of oral science 2019;11:1-13.
• Almehmadi AH, Alghamdi F. Biomarkers of alveolar bone resorption in gingival crevicular fluid: a systematic review. Archives of oral biology 2018;93:12-21.
• Shazam H, Shaikh F, Hussain Z. Bone Turnover Markers in Chronic Periodontitis: A Literature Review. Cureus 2020;12.
• Page RC, Kornman KS. The pathogenesis of human periodontitis: an introduction. Periodontology 2000 1997;14:9-11.
• Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontology 2000 2014;64:57-80.
• Zhou M, Li S, Pathak JL. Pro-inflammatory cytokines and osteocytes. Current osteoporosis reports 2019;17:97-104.
• Hienz SA, Paliwal S, Ivanovski S. Mechanisms of bone resorption in periodontitis. Journal of immunology research 2015;2015.
• Champagne CM, Buchanan W, Reddy MS, Preisser JS, Beck JD, Offenbacher S. Potential for gingival crevice fluid measures as predictors of risk for periodontal diseases. Periodontology 2000 2003;31:167-180.
• Kinney JS, Ramseier CA, Giannobile WV. Oral fluid-based biomarkers of alveolar bone loss in periodontitis. Annals of the New York Academy of Sciences 2007;1098:230.
• AlRowis R, AlMoharib HS, AlMubarak A, Bhaskardoss J, Preethanath R, Anil S. Oral fluid-based biomarkers in periodontal disease–Part 2. Gingival crevicular fluid. Journal of international oral health: JIOH 2014;6:126.
• Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. Journal of Bone and Mineral Research 2013;28:2347-2356.
• Chatzopoulos GS, Mansky KC, Lunos S, Costalonga M, Wolff LF. Sclerostin and WNT‐5a gingival protein levels in chronic periodontitis and health. Journal of periodontal research 2019.
• Slot DE, De Geest S, van der Weijden FA, Quirynen M. Treatment of oral malodour. Medium‐term efficacy of mechanical and/or chemical agents: a systematic review. Journal of clinical periodontology 2015;42:S303-S316.
• Ji S, Choi Y. Point-of-care diagnosis of periodontitis using saliva: technically feasible but still a challenge. Frontiers in cellular and infection microbiology 2015;5:65.
• Barros SP, Williams R, Offenbacher S, Morelli T. Gingival crevicular fluid as a source of biomarkers for periodontitis. Periodontology 2000 2016;70:53-64.
• Donos N. The periodontal pocket. Periodontology 2000 2018;76:7-15.
• Jaedicke KM, Preshaw PM, Taylor JJ. Salivary cytokines as biomarkers of periodontal diseases. Periodontology 2000 2016;70:164-183.
• de Vries TJ, Huesa C. The Osteocyte as a Novel Key Player in Understanding Periodontitis Through its Expression of RANKL and Sclerostin: a Review. Current osteoporosis reports 2019;17:116-121.
• Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone 2017;96:29-37.
• Holdsworth G, Roberts SJ, Ke HZ. Novel actions of sclerostin on bone. Journal of molecular endocrinology 2019;62:R167-R185.
• Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004;9:2273-2284.
• Du Y-Y, Zhao Y-X, Liu Y-P, Liu W, Wang M-M, Yuan C-M. Regulatory Tweak/Fn14 signaling pathway as a potent target for controlling bone loss. Biomedicine & Pharmacotherapy 2015;70:170-173.
• Findlay DM, Atkins GJ. TWEAK and TNF regulation of sclerostin: a novel pathway for the regulation of bone remodelling. In: Advances in TNF Family Research: Springer, 2011:337-348.
• Vincent C, Findlay DM, Welldon KJ, et al. Pro‐inflammatory cytokines TNF‐related weak inducer of apoptosis (TWEAK) and TNFα induce the mitogen‐activated protein kinase (MAPK)‐dependent expression of sclerostin in human osteoblasts. Journal of bone and mineral research 2009;24:1434-1449.
• Kim JH, Lee DE, Cha JH, Bak EJ, Yoo YJ. Receptor activator of nuclear factor‐κB ligand and sclerostin expression in osteocytes of alveolar bone in rats with ligature‐induced periodontitis. Journal of periodontology 2014;85:e370-e378.
• Kim J, Lee D, Woo G, Cha J, Bak E, Yoo Y. Osteocytic sclerostin expression in alveolar bone in diabetic rats with ligature induced-periodontitis. J Periodontol 2015;86:1005-1011.
• Yang X, Han X, Shu R, et al. Effect of sclerostin removal in vivo on experimental periodontitis in mice. Journal of oral science 2016;58:271-276.
• Sankardas PA, Lavu V, Lakakula BV, Rao SR. Differential expression of periostin, sclerostin, receptor activator of nuclear factor‐κB, and receptor activator of nuclear factor‐κB ligand genes in severe chronic periodontitis. Journal of investigative and clinical dentistry 2019;10:e12369.
• Miranda TS, Napimoga MH, Feres M, et al. Antagonists of Wnt/β‐catenin signalling in the periodontitis associated with type 2 diabetes and smoking. Journal of clinical periodontology 2018;45:293-302.
• Napimoga MH, Nametala C, da Silva FL, et al. Involvement of the Wnt‐β‐catenin signalling antagonists, sclerostin and dickkopf‐related protein 1, in chronic periodontitis. Journal of clinical periodontology 2014;41:550-557.
• Fattori V, Pinho‐Ribeiro FA, Staurengo‐Ferrari L, et al. The specialised pro‐resolving lipid mediator maresin 1 reduces inflammatory pain with a long‐lasting analgesic effect. British journal of pharmacology 2019;176:1728-1744.
• Rezaei Esfahrood Z, Yadegari Z, Veysari SK, Kadkhodazadeh M. Gingival crevicular fluid levels of sclerostin in chronic periodontitis and healthy subjects. Journal of the Korean Association of Oral and Maxillofacial Surgeons 2018;44:289-292.
• Balli U, Aydogdu A, Dede FO, Turer CC, Guven B. Gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor‐κB ligand in periodontitis. Journal of periodontology 2015;86:1396-1404.
• Beiler TF, de Mello Neto JM, Alves JC, Hamlet S, Ipe D, da Silva Figueredo CM. Impact of non-surgical periodontal treatment on salivary expression of cytokines related to bone metabolism. Odontology 2020:1-7.
• Pai BJ, Krishnan NR, Walveker A, et al. Comparative evaluation of sclerostin levels in gingival crevicular fluid in the treatment of chronic periodontitis patients using diode laser as an adjunct to scaling and root planing: A clinico-biochemical study. Contemporary Clinical Dentistry 2021;12:276.
• Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T. Proinflammatory effects of tumour necrosis factor‐like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clinical & Experimental Immunology 2006;146:540-549.
• Kataria N, Bartold P, Dharmapatni A, Atkins G, Holding C, Haynes D. Expression of tumor necrosis factor‐like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor‐inducible 14 protein (Fn14), in healthy tissues and in tissues affected by periodontitis. Journal of periodontal research 2010;45:564-573.
• Acharya AB, Chandrashekar A, Acharya S, Shettar L, Thakur S. Serum sTWEAK levels in chronic periodontitis and type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:1609-1613.
• Leira Y, Ameijeira P, Domínguez C, et al. Severe periodontitis is linked with increased peripheral levels of sTWEAK and PTX3 in chronic migraineurs. Clinical oral investigations 2020;24:597-606.
• Panezai J, Ali A, Ghaffar A, et al. Upregulation of circulating inflammatory biomarkers under the influence of periodontal disease in rheumatoid arthritis patients. Cytokine 2020;131:155117.
• Panezai J, Ghaffar A, Altamash M, Sundqvist K-G, Engström P-E, Larsson A. Correlation of serum cytokines, chemokines, growth factors and enzymes with periodontal disease parameters. PloS one 2017;12:e0188945.
• Yakar N, Guncu GN, Akman AC, Pınar A, Karabulut E, Nohutcu RM. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG. Cytokine 2019;113:433-439.
• Gur AT, Guncu GN, Akman AC, Pinar A, Karabulut E, Nohutcu RM. Evaluation of GCF IL‐17, IL‐10, TWEAK and sclerostin levels after SRP and adjunctive use of diode laser application in periodontitis patients. Journal of periodontology 2021.